AKRO
Akero Therapeutics Inc
NASDAQ: AKRO · HEALTHCARE · BIOTECHNOLOGY
$54.65
+0.00% today
Updated 2025-12-09
Market cap
$4.50B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.75
Dividend yield
—
52W range
$32 – $57
Volume
2.9M
WallStSmart proprietary scores
27
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.0
Quality
A3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
4.6
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$56.50
+3.39%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Altman Z 4.61 — safe zone
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-67.17M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-100.74M | $-112.03M | $-151.76M | $-252.06M | $-81.57M |
| EPS | — | — | — | — | $-3.75 |
| Free cash flow | $-79.68M | $-92.52M | $-145.37M | $-231.11M | $-67.17M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Akero Therapeutics Inc trades at $54.65. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 4.61, it sits in the safe zone.
Frequently asked questions
What is Akero Therapeutics Inc's stock price?
Akero Therapeutics Inc (AKRO) trades at $54.65.
Is Akero Therapeutics Inc overvalued?
Akero Therapeutics Inc carries a Smart Value Score of 27/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Akero Therapeutics Inc (AKRO)?
The 12-month analyst consensus target is $56.50, about 3.4% above the current $54.65. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Akero Therapeutics Inc's Altman Z-Score is 4.61, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-30.58%
Beta-0.40
50D MA$53.20
200D MA$48.24
Shares out0.08B
Float0.07B
Short ratio—
Avg volume2.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—